Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Updated immunization strategies are needed to address multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an ongoing, open-label phase 2/3 trial evaluating the safety and immunogenicity of the bivalent Coronavirus Disease 2019 (COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalkias, Spyros, Eder, Frank, Essink, Brandon, Khetan, Shishir, Nestorova, Biliana, Feng, Jing, Chen, Xing, Chang, Ying, Zhou, Honghong, Montefiori, David, Edwards, Darin K., Girard, Bethany, Pajon, Rolando, Dutko, Frank J., Leav, Brett, Walsh, Stephen R., Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671805/
https://www.ncbi.nlm.nih.gov/pubmed/36202997
http://dx.doi.org/10.1038/s41591-022-02031-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671805/
https://www.ncbi.nlm.nih.gov/pubmed/36202997
http://dx.doi.org/10.1038/s41591-022-02031-7

Ejemplares similares